Toll Free: 1-888-928-9744

Benign Prostatic Hyperplasia - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 128 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Benign Prostatic Hyperplasia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Benign Prostatic Hyperplasia - Pipeline Review, H1 2016', provides an overview of the Benign Prostatic Hyperplasia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia
- The report reviews pipeline therapeutics for Benign Prostatic Hyperplasia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Benign Prostatic Hyperplasia therapeutics and enlists all their major and minor projects
- The report assesses Benign Prostatic Hyperplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Benign Prostatic Hyperplasia Overview 10 Therapeutics Development 11 Pipeline Products for Benign Prostatic Hyperplasia - Overview 11 Pipeline Products for Benign Prostatic Hyperplasia - Comparative Analysis 12 Benign Prostatic Hyperplasia - Therapeutics under Development by Companies 13 Benign Prostatic Hyperplasia - Therapeutics under Investigation by Universities/Institutes 15 Benign Prostatic Hyperplasia - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Benign Prostatic Hyperplasia - Products under Development by Companies 20 Benign Prostatic Hyperplasia - Products under Investigation by Universities/Institutes 22 Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development 23 AndroScience Corporation 23 Aphios Corporation 24 Ausio Pharmaceuticals, LLC 25 BCWorld Pharm Co. Ltd. 26 Chong Kun Dang Pharmaceutical Corp. 27 Dongkook Pharmaceutical Co., Ltd. 28 Euroscreen S.A. 29 Hanmi Pharmaceuticals, Co. Ltd. 30 Jeil Pharmaceutical Co., Ltd. 31 Kaken Pharmaceutical Co., Ltd. 32 Meiji Seika Pharma Co., Ltd. 33 Mezzion Pharma Co. Ltd. 34 Monosol Rx, LLC 35 Nymox Pharmaceutical Corporation 36 Ono Pharmaceutical Co., Ltd. 37 Sihuan Pharmaceutical Holdings Group Ltd. 38 SK Chemicals Co., Ltd. 39 SOM Innovation Biotech SL 40 Sophiris Bio, Inc. 41 Yungjin Pharm. Co., Ltd. 42 Benign Prostatic Hyperplasia - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Combination Products 44 Assessment by Target 45 Assessment by Mechanism of Action 47 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 (dutasteride + tadalafil) - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 (solifenacin succinate + tamsulosin hydrochloride) - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 (tadalafil + tamsulosin hydrochloride) - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 ASC-JM.X2 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 AUS-131 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 BCWPE-004 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 BL-214 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 CKD-902 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 ESN-364 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 fadanafil - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 fexapotide triflutate - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 HCP-1303 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 HIP-1402 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 L-1AD3 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 MCS-2 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 NCE-403 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 ONO-8430506 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 S-40542 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 SL-052 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 SOM-2391 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 SOM-2393 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Sperol - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 tadalafil - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 talaporfin sodium - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 tamsulosin hydrochloride CR - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 tamsulosin hydrochloride DR - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 tertomotide - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 topsalysin - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 udenafil - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 YBH-1603 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 YOB-1604 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Benign Prostatic Hyperplasia - Recent Pipeline Updates 97 Benign Prostatic Hyperplasia - Dormant Projects 116 Benign Prostatic Hyperplasia - Discontinued Products 120 Benign Prostatic Hyperplasia - Product Development Milestones 121 Featured News & Press Releases 121 May 05, 2016: Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting 121 Apr 01, 2015: Nymox Announces Phase 3 BPH Studies 121 Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 121 Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints 122 Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 122 Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH 123 Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study 124 Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207 124 Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug 125 May 08, 2014: Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH 126 Appendix 127 Methodology 127 Coverage 127 Secondary Research 127 Primary Research 127 Expert Panel Validation 127 Contact Us 127 Disclaimer 128
List of Tables
Number of Products under Development for Benign Prostatic Hyperplasia, H1 2016 11 Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Development by Companies, H1 2016 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Comparative Analysis by Unknown Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Investigation by Universities/Institutes, H1 2016 22 Benign Prostatic Hyperplasia - Pipeline by AndroScience Corporation, H1 2016 23 Benign Prostatic Hyperplasia - Pipeline by Aphios Corporation, H1 2016 24 Benign Prostatic Hyperplasia - Pipeline by Ausio Pharmaceuticals, LLC, H1 2016 25 Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co. Ltd., H1 2016 26 Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 27 Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2016 28 Benign Prostatic Hyperplasia - Pipeline by Euroscreen S.A., H1 2016 29 Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 30 Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 31 Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016 32 Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016 33 Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co. Ltd., H1 2016 34 Benign Prostatic Hyperplasia - Pipeline by Monosol Rx, LLC, H1 2016 35 Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corporation, H1 2016 36 Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 37 Benign Prostatic Hyperplasia - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 38 Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co., Ltd., H1 2016 39 Benign Prostatic Hyperplasia - Pipeline by SOM Innovation Biotech SL, H1 2016 40 Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio, Inc., H1 2016 41 Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 42 Assessment by Monotherapy Products, H1 2016 43 Assessment by Combination Products, H1 2016 44 Number of Products by Stage and Target, H1 2016 46 Number of Products by Stage and Mechanism of Action, H1 2016 48 Number of Products by Stage and Route of Administration, H1 2016 50 Number of Products by Stage and Molecule Type, H1 2016 52 Benign Prostatic Hyperplasia Therapeutics - Recent Pipeline Updates, H1 2016 97 Benign Prostatic Hyperplasia - Dormant Projects, H1 2016 116 Benign Prostatic Hyperplasia - Dormant Projects (Contd..1), H1 2016 117 Benign Prostatic Hyperplasia - Dormant Projects (Contd..2), H1 2016 118 Benign Prostatic Hyperplasia - Dormant Projects (Contd..3), H1 2016 119 Benign Prostatic Hyperplasia - Discontinued Products, H1 2016 120


List of Figures
Number of Products under Development for Benign Prostatic Hyperplasia, H1 2016 11 Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Products, H1 2016 18 Assessment by Monotherapy Products, H1 2016 43 Assessment by Combination Products, H1 2016 44 Number of Products by Top 10 Targets, H1 2016 45 Number of Products by Stage and Top 10 Targets, H1 2016 45 Number of Products by Top 10 Mechanism of Actions, H1 2016 47 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 47 Number of Products by Routes of Administration, H1 2016 49 Number of Products by Stage and Routes of Administration, H1 2016 49 Number of Products by Molecule Types, H1 2016 51 Number of Products by Stage and Molecule Types, H1 2016 51

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among ot

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealan

Read More...

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify